<DOC>
	<DOC>NCT01885208</DOC>
	<brief_summary>This trial is conducted in Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of semaglutide once-weekly versus exenatide ER (extended release) 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Subjects diagnosed with type 2 diabetes and on stable diabetes treatment with 12 OADs (Metformin equal to or above 1500 mg or maximum tolerated dose and/or thiazolidinedione (TZD) and sulfonylureas (SUs) equal to or above half of maximum dose allowed according to national label) for at least 90 days prior to screening. Stable is defined as unchanged medication and unchanged dose HbA1c 7.0 10.5 % (53 91 mmol/mol) (both inclusive) Females of childbearing potential who are pregnant, breastfeeding or intend to become pregnant or are not using an adequate contraceptive method throughout the trial including the 5 week followup period (adequate contraceptive measures as required by local law or practice) Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol Treatment with glucose lowering agent(s) other than stated in the inclusion criteria in a period of 90 days before screening. An exception is shortterm treatment (7 days or less in total) with insulin in connection with intercurrent illness History of chronic or idiopathic acute pancreatitis Screening calcitonin value equal to or above 50 ng/L (pg/mL) Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) Impaired renal function defined as estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m^2 per modification of diet in renal disease (MDRD) formula (4 variable version) Acute coronary or cerebrovascular event within 90 days before randomisation Heart failure, New York Heart Association (NYHA) class IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>